Genentech/OSI Tarceva Shows Two-Month Improvement Over Placebo

A placebo-controlled, Phase III study presented at ASCO found a survival benefit in Tarceva patients with refractory non-small cell lung cancer. The rolling NDA is expected to be completed this summer.